Rain Therapeutics is an American clinical-stage precision oncology company, engages in developing therapies that target oncogenic drivers. Rain Therapeutics was incorporated in 2017 and is headquartered in Newark, California.
P/E
Net profit
P/B
Book value
P/FCF
FCF
Yield
Growth potential
Rain Therapeutics news
05.05.2022
Rain Therapeutics' GAAP loss for 3 months of 2022 was $17.394 million, up 2.5 times from $6.8 million in the previous year.
Source: 
investors.rainthera.com
investors.rainthera.com
04.03.2022
Rain Therapeutics' GAAP loss for 2021 was $51.394 million, up 2.4 times from $21.083 million in the previous year.
Source: investors.rainthera.com
investors.rainthera.com
10.11.2021
Rain Therapeutics' GAAP loss for 9M 2021 was $33.409 million, up 2.1 times from $15.64 million in the previous year.
Source: investors.rainthera.com
investors.rainthera.com
General information
| Company name | Rain Therapeutics |
|---|---|
| Tags | #biotechnology, #cancer treatment |
| Sector | Health Care / Pharmaceuticals, Biotechnology & Life Sciences / Biotechnology / Biotechnology |
| Business address | 8000 Jarvis Avenue Suite 204 Newark, CA 94560-7467 United States |
| Mailing address | 8000 Jarvis Avenue Suite 204 Newark, CA 94560-7467 United States |
| Website | investors.rainthera.com |
English (US) 